ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

MTNB Matinas Biopharma Holdings Inc

0.1756
-0.0011 (-0.62%)
2024年5月11日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Matinas Biopharma Holdings Inc MTNB AMEX 普通株式
  前日比 前日比 % 現在値 時刻
-0.0011 -0.62% 0.1756 09:00:00
始値 安値 高値 終値 前日終値
0.1767 0.1673 0.177 0.1756 0.1767
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/1005:06EDGAR2Form 8-K - Current report
2024/5/1005:05GLOBEMatinas BioPharma Reports First Quarter 2024 Financial..
2024/5/1005:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/0721:00GLOBEMatinas BioPharma’s LNC Platform for the Delivery of Small..
2024/5/0220:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
2024/4/3021:00GLOBEIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in..
2024/4/0321:30GLOBEMatinas BioPharma Prices $10 Million Registered Direct..
2024/3/2805:05GLOBEMatinas BioPharma Reports 2023 Financial Results and..
2024/3/2521:00GLOBEMatinas BioPharma Announces Positive in vivo Safety Data..
2024/3/2222:15GLOBEThree Patients with Invasive Fusarium Infection in Matinas..
2024/3/2219:30GLOBEMatinas BioPharma Regains Compliance with NYSE American..
2024/2/2622:05EDGAR2Form 8-K - Current report
2024/2/2622:00GLOBEMatinas BioPharma Provides Positive Outcomes Update on the..
2024/2/2021:35EDGAR2Form 8-K - Current report
2024/2/2021:30GLOBEMatinas BioPharma Successfully Reaches Agreement with FDA..
2024/1/0921:30EDGAR2Form 8-K - Current report
2024/1/0321:00GLOBEMatinas BioPharma to Present at Biotech Showcase 2024
2023/12/2721:40EDGAR2Form 8-K - Current report
2023/12/2721:30GLOBEMatinas BioPharma Demonstrates in vivo Biological Activity..
2023/12/2121:40EDGAR2Form 8-K - Current report
2023/12/2121:30GLOBEMatinas BioPharma Provides Update to MAT2203 Regulatory and..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1611:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2021:30EDGAR2Form 8-K - Current report
2023/11/1007:25EDGAR2Form 8-K - Current report
2023/11/0906:06EDGAR2Form 8-K - Current report
2023/11/0906:05GLOBEMatinas BioPharma Reports Third Quarter 2023 Financial..
2023/11/0906:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0721:30GLOBEMatinas BioPharma Announces Positive in vivo Efficacy..
2023/11/0405:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0306:20EDGAR2Form 8-K - Current report
2023/11/0120:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
2023/10/1123:25APSBiotech Catches Massive Premarket Bid
2023/10/1120:30GLOBEPatient with Candida krusei Infection in Matinas BioPharma’s..
2023/9/2820:00GLOBEMatinas BioPharma to Present at Two Investment Conferences..
2023/9/2720:00GLOBEMatinas BioPharma to Feature MAT2203 in a Pipeline..
2023/9/2306:25EDGAR2Form 8-K - Current report
2023/9/2306:25GLOBEMatinas BioPharma Announces Notification of NYSE American..
2023/9/2122:35GLOBEDawson James Securities Announces October Date for 8th..
2023/9/2020:30EDGAR2Form 8-K - Current report
2023/9/2006:25EDGAR2Form DEF 14A - Other definitive proxy statements
2023/9/0906:15EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/9/0620:00GLOBEMatinas BioPharma to Participate in the H.C. Wainwright..
2023/8/2220:30GLOBEMatinas BioPharma Announces Publication of Results from the..
2023/8/1005:06EDGAR2Form 8-K - Current report
2023/8/1005:05GLOBEMatinas BioPharma Reports Second Quarter 2023 Financial..

最近閲覧した銘柄

Delayed Upgrade Clock